Copyright timesnownews
Dilbert comic strip creator Scott Adams has appealed directly to President Donald Trump for help in obtaining treatment for his advanced prostate cancer. In a post on X (formerly Twitter) on Sunday, Adams wrote: "On Monday, I will ask President Trump, via X, to help save my life. He offered to help me if I needed it. I need it." Adams said he is suffering from metastasized prostate cancer and is struggling to secure access to a new cancer drug, Pluvicto, approved by the US Food and Drug Administration (FDA) in 2022. He said his healthcare provider, Kaiser Permanente of Northern California, had initially approved his application to receive the treatment but "dropped the ball in scheduling the brief IV to administer it and I can't seem to fix that." "I am declining fast," Adams wrote. "I will ask President Trump if he can get Kaiser of Northern California to respond and schedule it for Monday. That will give me a fighting chance to stick around on this planet a little bit longer." He added that Pluvicto was not a "cure" but had shown "good results to many people." What Has Trump Said? Adams' post quickly drew responses from members of the Trump administration and the president's family. President Trump shared Adams' post on his Truth Social platform and replied that he was "on it." Robert F Kennedy Jr, the US Secretary of Health, wrote on X: "Scott. How do I reach you? The President wants to help." Dan Scavino Jr, White House Deputy Chief of Staff, also responded: "No need to wait until Monday — @realDonaldTrump, @RobertKennedyJr, and @DrOz are all tracking now, Scott," adding a prayer emoji. Donald Trump Jr said he would make sure his father saw Adams' message, posting: "We're all praying for you, keep fighting!" Who is Scott Adams? Adams, 67, is best known as the creator of the Dilbert comic strip, which became widely popular in the 1990s for its satirical take on office culture. He has also written several books, including Loserthink and God's Debris. He has been an outspoken supporter of Donald Trump, having endorsed him during the 2016 presidential election after previously supporting Mitt Romney. In 2016, Adams predicted Trump would win the presidency — a forecast that brought him national attention as Trump's campaign gained momentum. Some of his later political predictions, however, were controversial. In 2020, he suggested that Republicans "would be hunted" if Joe Biden won the election, and he later claimed the 2024 election would end in a "landslide" of fraud allegations and that the results would be overturned by the Supreme Court — none of which occurred. Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a radioligand therapy (RLT) used to treat adults with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). Approved by the FDA in 2022, it targets PSMA — a biomarker found on many prostate cancer cells. The drug is designed to "find and attack PSMA+ cells, including cancer cells," while potentially affecting some healthy cells. Pluvicto is administered intravenously, which Adams said was the source of his difficulty — claiming that Kaiser Permanente had failed to schedule the brief IV session needed to deliver the treatment. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US News and around the World.
